使用神经血管结构邻近冰冻切片检查(NeuroSAFE)的保留神经根治性前列腺切除术:20年经验结果
该研究对2002年1月至2011年6月间11069例伴或不伴NeuroSAFE的根治性前列腺切除术进行10年生存分析,中位随访121个月。NeuroSAFE组与非NeuroSAFE组的10年生化复发无生存率在pT2、pT3a、≥pT3b亚组均无显著差异,但NeuroSAFE组1年勃起功能更优(68% vs 58%,p=0.02),1年和2年控尿率无差异。
要点
- NeuroSAFE组与非NeuroSAFE组10年生化复发无生存率在pT2、pT3a、≥pT3b亚组均无显著差异。
- NeuroSAFE组1年勃起功能优于非NeuroSAFE组(68% vs 58%,p=0.02)。
- 两组1年和2年控尿率无差异。
核心结论
- NeuroSAFE方法未显著改善长期肿瘤学或控尿结局,但可能通过增加保留神经手术比例为更高比例患者改善术后功能结果。
研究设计与样本
- 对2002年1月至2011年6月间实施的11069例伴或不伴NeuroSAFE的根治性前列腺切除术进行10年生存分析。
- 在NeuroSAFE队列中,根治性前列腺切除术中切除神经血管结构邻近前列腺切缘并进行冰冻切片染色。
- 若切缘阳性,则行部分或全部神经血管束切除。
- 采用倾向性评分匹配队列评估1年勃起功能以及1年和2年控尿率。
主要发现
- 中位随访121个月(IQR:73,156)。
- 10年生化复发无生存率:NeuroSAFE组 vs 非NeuroSAFE组,pT2为81% vs 84%(p=0.06),pT3a为58% vs 63%(p=0.6),≥pT3b为22% vs 27%(p=0.99)。
- salvage放射治疗无生存率两组间无差异(pT2:p=0.1;pT3a:p=0.4;≥pT3b:p=0.4)。
- 无转移生存率两组间无差异(pT2:p=0.3;pT3a:p=0.6;≥pT3b:p=0.9)。
- NeuroSAFE组1年勃起功能优于非NeuroSAFE组(68% vs 58%,p=0.02)。
局限性
- 主要局限性为回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the long-term oncological outcomes and functional results of the neurovascular structure-adjacent frozen-section examination (NeuroSAFE) during nerve-sparing (NS) radical prostatectomy (RP). MATERIALS AND METHODS: A 10-yr survival analysis on 11069 RPs performed with or without the NeuroSAFE, between January 2002 to June 2011 was carried out. In the NeuroSAFE cohort, the neurovascular structure-adjacent prostatic margins are removed and stained for cryo-sectioning during RP. In case of a PSM, partial or full removal of the neurovascular bundle was performed. The impact of NeuroSAFE on biochemical recurrence-free survival (BFS), salvage radiation therapy-free survival, metastasis-free survival, and prostate cancer-specific survival at 10 years was analyzed. 1-year (1-yr) erectile function (EF), 1-yr, and 2-yr continence rates were assessed in propensity score-based matched cohorts. RESULTS: Median follow-up was 121 (IQR: 73, 156) months. No differences in BFS between NeuroSAFE and non-NeuroSAFE were recorded (10-yr BFS: NeuroSAFE vs non-Neurosafe, pT2: 81% vs 84%, p = 0.06; pT3a: 58% vs. 63%, p = 0.6; ≥pT3b: 22% vs. 27%, p = 0.99). No differences were found between the two groups in terms of sRFS (pT2: p = 0.1; pT3a: p = 0.4; ≥pT3b: p = 0.4) (Fig. 1B, Table 2), and MTS (pT2: p = 0.3; pT3a: p = 0.6; ≥pT3b: p = 0.9). The NeuroSAFE-navigated patients reported a better 1-yr EF than non-NeuroSAFE (68% vs. 58%, p = 0.02) and no differences in 1-yr and 2-yr continence rates (92.4% vs. 91.8%, and 93.4% vs. 93%, respectively). The main limitation is the retrospective study design. CONCLUSIONS: While the NeuroSAFE approach did not show significant improvements in long-term oncologic or continence outcomes, it did provide an opportunity for a higher proportion of patients to improve postoperative functional results, possibly through increased nerve-sparing procedures.
引用
- Ambrosini F, Preisser F, Tilki D, et al. Nerve-sparing radical prostatectomy using the neurovascular structure-adjacent frozen-section examination (NeuroSAFE): results after 20 years of experience. Prostate Cancer Prostatic Dis. 2024. PMID: 38862777. doi:10.1038/s41391-024-00851-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。